On May 8, 2018, Hansoh’s anti-infective drug Hengjie (Linezolid Glucose Injection) (packed in soft bag, available in 100ml containing 0.2g of linezolid and 4.6g of anhydrous glucose and 300ml containing 0.6g of linezolid and 13.8g of anhydrous glucose) received NDA approval from National Medical Products Administration as the first-to-market generic of antibiotic linezolid in China.

Linezolid is a new synthetic antibiotic that inhibits bacterial protein synthesis and fully covers Gram-positive bacteria. It is indicated for the treatment of infections caused by certain sensitive strains of microorganisms, including infections caused by vancomycin-resistant enterococcus, nosocomial pneumonia, complicated skin and skin structure infections, uncomplicated skin and skin structure infections, and community-acquired pneumonia and concomitant staphylococcemia.